<DOC>
	<DOC>NCT00715702</DOC>
	<brief_summary>The purpose of the study is to investigate the pharmacokinetics of a single dose of AZD5672 in patients with renal impairment by comparing with healthy volunteers</brief_summary>
	<brief_title>Safety Study of AZD5672 in Renally Impaired Subjects</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>N-(1-(3-(3,5-difluorophenyl)-3-(4-methanesulfonylphenyl)propyl)piperidin-4-yl)-N-ethyl-2-(4-methanesulfonylphenyl)acetamide</mesh_term>
	<criteria>Provision of signed written informed consent. Females should not be of childbearing potential Subjects classified as renally impaired should have been stable (in the Investigator's opinion) for at least 3 months prior to Visit 1. Patients taking prescription of medications: Pgp substrates, inhibitors and /or inducers, medications that affect creatinine clearance(within 7 days of dosing), atorvastatin &gt;20mg once daily, medications that prolong QT/QTc interval Change in dose regimen of prescribed medication and NSAIDs within the 2 weeks before enrolment (renal patients only) Participation in another clinical study involving administration of an investigational product in the 3 months prior to treatment (or within 5 halflives of the last dose of the investigational product, whichever is longer)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>AZD5672</keyword>
</DOC>